In the News We’re proud to share that Dr. Gregory Vidal was recently featured in DocWire News.
In this article, “Exploring the evERA BC Trial With Dr. Gregory Vidal: Improving Endocrine Response Beyond CDK4/6 Resistance,” Dr. Vidal discusses findings presented at ESMO 2025 from the phase 3 evERA BC trial—which investigated giredestrant plus everolimus in patients with ER+/HER2– advanced #BreastCancer following CDK4/6 inhibitor therapy.
Dr. Vidal shares how this research builds upon prior studies involving mTOR inhibition, explores the challenges of trial design in the post-CDK4/6 setting, and considers how giredestrant-based combinations could shape the future of breast cancer treatment.